PTC Therapeutics

PTC Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of orally-administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company's lead product, Translarna, is used for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients with age of over five years and older. Its programs include Translarna for nonsense mutation cystic fibrosis, Translarna for mucopolysaccharidosis type I caused by nonsense mutation, Translarna for nonsense mutation aniridia, and Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy in collaboration with Spinal Muscular Atrophy Foundation.
Company Growth (employees)
Type
Public
HQ
South Plainfield, US
Founded
1998
Size (employees)
298 (est)-6%
Website
ptcbio.com
PTC Therapeutics was founded in 1998 and is headquartered in South Plainfield, US

PTC Therapeutics Office Locations

PTC Therapeutics has an office in South Plainfield
South Plainfield, US (HQ)
100 Corporate Ct

PTC Therapeutics Data and Metrics

PTC Therapeutics Financial Metrics

PTC Therapeutics's revenue was reported to be $26.5 m in Q1, 2017
USD

Revenue (Q1, 2017)

26.5 m

Gross profit (Q1, 2017)

26.5 m

Gross profit margin (Q1, 2017), %

100%

Net income (Q1, 2017)

(29.1 m)

EBIT (Q1, 2017)

(26.4 m)

Market capitalization (25-Jul-2017)

725.6 m

Cash (31-Mar-2017)

54.1 m
PTC Therapeutics's current market capitalization is $725.6 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

34.7 m25.2 m36.8 m82.7 m

Revenue growth, %

(27%)46%125%

Operating expense total

80.1 m124.7 m203.9 m214.8 m

EBIT

(45.4 m)(99.4 m)(167.1 m)(132.1 m)

EBIT margin, %

(131%)(394%)(455%)(160%)

Interest expense

6.1 m1.2 m

Interest income

1.2 m

Income tax expense

(485 k)(569 k)

Net Income

(66.4 m)(93.8 m)(170.4 m)(142.1 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

1.7 m1.7 m7.5 m6.8 m9.8 m18.9 m15.6 m23 m26.5 m

Cost of goods sold

39 k

Gross profit

26.5 m

Gross profit Margin, %

100%

R&D expense

18.3 m18.8 m27.9 m28.2 m30.6 m31.4 m28.8 m31.4 m27.4 m

General and administrative expense

8.7 m10.5 m17.6 m17.2 m21.4 m25.9 m23.4 m23.7 m25.5 m

Operating expense total

27 m29.3 m45.6 m45.4 m52 m57.3 m52.2 m55.1 m52.9 m

EBIT

(25.4 m)(27.6 m)(38.1 m)(38.6 m)(42.2 m)(38.4 m)(36.6 m)(32.1 m)(26.4 m)

EBIT margin, %

(1513%)(1629%)(509%)(570%)(432%)(203%)(234%)(139%)(99%)

Interest expense

248 k354 k(2.2 m)

Interest income

248 k354 k524 k498 k

Income tax expense

(145 k)(88 k)(114 k)93 k(184 k)(165 k)

Net Income

(39.2 m)(66.5 m)(37.9 m)(76.3 m)(119.5 m)(41.2 m)(80.1 m)(115.3 m)(29.1 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

15.4 m49.7 m58 m58.3 m

Accounts Receivable

11.1 m24.9 m

Inventories

1.6 m3.9 m5.9 m4.7 m

Current Assets

145 m323.6 m355.9 m261.3 m

Total Assets

151.9 m333.2 m368 m269.3 m

Accounts Payable

12.2 m29.1 m45.2 m48.8 m

Total Debt

98.2 m

Current Liabilities

13.1 m32.5 m45.4 m49.6 m

Total Liabilities

149.8 m

Additional Paid-in Capital

465.2 m721.7 m820.2 m856.1 m

Retained Earnings

(328.8 m)(422.6 m)(593 m)(735.1 m)

Total Equity

136.5 m298.5 m226 m119.6 m

Debt to Equity Ratio

0.8 x

Debt to Assets Ratio

0.4 x

Financial Leverage

1.1 x1.1 x1.6 x2.3 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

21.2 m52.9 m36.8 m29.2 m140.7 m40.2 m35.7 m50.3 m54.1 m

Accounts Receivable

22.6 m19.8 m27.4 m32.2 m

Inventories

1.4 m

Current Assets

230.3 m213.5 m289.8 m264.6 m384.2 m326.4 m297.4 m280.6 m240.7 m

Total Assets

237.6 m220.8 m299.5 m273.8 m396.1 m335.2 m305.6 m288.2 m248.6 m

Accounts Payable

11.3 m16.5 m23.5 m23.1 m31.7 m43.5 m42.2 m47.8 m45.2 m

Current Liabilities

11.6 m17.3 m23.9 m23.1 m31.7 m43.9 m42.9 m48.9 m45.4 m

Additional Paid-in Capital

591.6 m596.6 m734.5 m747.9 m812.3 m829.1 m837.9 m847.7 m865.8 m

Retained Earnings

(368 m)(395.3 m)(460.5 m)(498.8 m)(542.1 m)(634.2 m)(673.1 m)(708.3 m)(764.2 m)

Total Equity

223.8 m201.3 m273.3 m248.6 m269.2 m196 m165.6 m140.2 m100.8 m

Financial Leverage

1.1 x1.1 x1.1 x1.1 x1.5 x1.7 x1.8 x2.1 x2.5 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(51.6 m)(93.8 m)(170.4 m)(142.1 m)

Depreciation and Amortization

2.4 m2.2 m2.9 m3.3 m

Accounts Receivable

(6.9 m)(14.8 m)

Inventories

(760.5 k)(2.3 m)(2.1 m)1.2 m

Accounts Payable

5.2 m16.9 m17 m4.3 m

Cash From Operating Activities

(46.9 m)(57.3 m)(124.3 m)(103.6 m)

Cash From Investing Activities

(127.8 m)(145.2 m)(20.8 m)104.5 m

Long-term Borrowings

(5 m)(49 k)(49 k)

Cash From Financing Activities

187.4 m237.1 m154.1 m968 k

Interest Paid

367.1 k1 k1 k4.5 m

Income Taxes Paid

2.1 k2 k111 k943 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(39.2 m)(66.5 m)(37.9 m)(76.3 m)(119.5 m)(41.2 m)(80.1 m)(115.3 m)(29.1 m)

Depreciation and Amortization

1.2 m1.7 m634 k1.3 m2.1 m849 k1.7 m2.5 m612 k

Accounts Receivable

(10.7 m)(8.5 m)(16 m)(6.7 m)

Inventories

(1.4 m)

Accounts Payable

(866 k)4.3 m(5.6 m)(6 m)2.9 m(2.5 m)(3.4 m)2.1 m(3.9 m)

Cash From Operating Activities

(32.2 m)(49.3 m)(36.4 m)(66.2 m)(94 m)(41.6 m)(66.2 m)(90.2 m)(28.9 m)

Cash From Investing Activities

(80.4 m)(32 m)37.3 m31 m22.1 m43.1 m81.4 m24.4 m

Long-term Borrowings

(49 k)(49 k)(37 k)(49 k)(49 k)

Cash From Financing Activities

118.4 m118.7 m3 m8.1 m154 m34 k34 k926 k663 k

Interest Paid

1 k1 k1 k1 k1 k2.3 m2.3 m4.5 m2.3 m

Income Taxes Paid

225 k264 k633 k28 k
USDY, 2017

Revenue/Employee

83 k

Financial Leverage

2.5 x

PTC Therapeutics Market Value History

PTC Therapeutics Online and Social Media Presence

PTC Therapeutics News and Updates

PTC Therapeutics Company Life and Culture

You may also be interested in